MedTrace Logo

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

NCT06553157 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-01-20

No results posted yet for this study

Summary

Platinum based chemotherapy (mainly Cisplatin) is known to cause a variety of adverse effects, including Ototoxicity and nephrotoxicity. Ototoxicity is estimated to affect about 36% of adult patients treated with cisplatin, many therapeutic interventions have been studied to reduce the risk of developing ototoxicity from Cisplatin treatment, Statins have been studied in animals and have shown promising results, this study is aimed to explore the effect of statins on the incidence of ototoxicity in humans.

Conditions

Interventions

DRUG

Statin

Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.

Sponsors & Collaborators

  • Minia University Hospital

    collaborator OTHER

  • Minia University

    lead OTHER

Principal Investigators

  • Noha H. Helmy, Masters · Department of Clinical Pharmacy, Faculty of Pharmacy, Minia University

  • Fatma M. Mady, Professor · Pharmaceutics Department, Faculty of Phramacy, Minia university

  • Nada H. Ali Sholkami, PhD · Department of Clinical Oncology, Faculty of Medicine, Minia University

  • Eman M. Sadek, PhD · Deaprtment of Clinical Pharmacy, Faculty of Pharmacy, Minia university

  • Dalia F. Mohammed Fahim, PhD · Department of ENT, Audio-Vestibular Unit, Faculty of Medicine,Minia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-07-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06553157 on ClinicalTrials.gov